Ferguson Wellman Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.6M | Sell |
182,260
-96
| -0.1% | -$14.4K | 0.35% | 64 |
|
|
2026
Q1 | $27.9M | Buy |
+182,356
| New | +$28M | 0.38% | 59 |
|
|
2021
Q1 | – | Sell |
-23,334
| Closed | -$2.2M | – | 377 |
|
|
2020
Q4 | $2.2M | Hold |
23,334
| – | – | 0.05% | 168 |
|
|
2020
Q3 | $2.03M | Sell |
23,334
-60
| -0.3% | -$5.2K | 0.06% | 163 |
|
|
2020
Q2 | $2.04M | Hold |
23,394
| – | – | 0.06% | 153 |
|
|
2020
Q1 | $1.93M | Sell |
23,394
-427
| -2% | -$38.1K | 0.07% | 149 |
|
|
2019
Q4 | $2.26M | Sell |
23,821
-222
| -0.9% | -$19.9K | 0.07% | 161 |
|
|
2019
Q3 | $2.09M | Buy |
24,043
+17,202
| +251% | +$1.54M | 0.07% | 156 |
|
|
2019
Q2 | $625K | Sell |
6,841
-794
| -10% | -$67.2K | 0.02% | 231 |
|
|
2019
Q1 | $658K | Sell |
7,635
-512
| -6% | -$41.1K | 0.02% | 234 |
|
|
2018
Q4 | $626K | Buy |
8,147
+335
| +4% | +$26.1K | 0.02% | 238 |
|
|
2018
Q3 | $603K | Buy |
7,812
+658
| +9% | +$48.6K | 0.02% | 229 |
|
|
2018
Q2 | $484K | Buy |
7,154
+320
| +5% | +$22.1K | 0.02% | 242 |
|
|
2018
Q1 | $495K | Sell |
6,834
-270
| -4% | -$20.6K | 0.02% | 246 |
|
|
2017
Q4 | $534K | Sell |
7,104
-1,256
| -15% | -$94.8K | 0.02% | 241 |
|
|
2017
Q3 | $643K | Hold |
8,360
| – | – | 0.02% | 218 |
|
|
2017
Q2 | $625K | Sell |
8,360
-379
| -4% | -$26.9K | 0.02% | 212 |
|
|
2017
Q1 | $582K | Sell |
8,739
-650
| -7% | -$43.3K | 0.02% | 219 |
|
|
2016
Q4 | $613K | Buy |
9,389
+1,107
| +13% | +$71.8K | 0.03% | 217 |
|
|
2016
Q3 | $586K | Sell |
8,282
-1,986
| -19% | -$145K | 0.03% | 198 |
|
|
2016
Q2 | $759K | Sell |
10,268
-1,879
| -15% | -$130K | 0.03% | 183 |
|
|
2016
Q1 | $788K | Buy |
12,147
+1,572
| +15% | +$107K | 0.03% | 191 |
|
|
2015
Q4 | $815K | Sell |
10,575
-111
| -1% | -$8.82K | 0.03% | 207 |
|
|
2015
Q3 | $880K | Buy |
10,686
+124
| +1% | +$11K | 0.04% | 199 |
|
|
2015
Q2 | $931K | Buy |
10,562
+2,873
| +37% | +$264K | 0.04% | 208 |
|
|
2015
Q1 | $679K | Buy |
7,689
+92
| +1% | +$8.16K | 0.03% | 225 |
|
|
2014
Q4 | $631K | Sell |
7,597
-167
| -2% | -$13.8K | 0.03% | 230 |
|
|
2014
Q3 | $655K | Sell |
7,764
-190
| -2% | -$15.4K | 0.03% | 208 |
|
|
2014
Q2 | $645K | Buy |
7,954
+1,249
| +19% | +$98.2K | 0.03% | 214 |
|
|
2014
Q1 | $511K | Sell |
6,705
-2,803
| -29% | -$204K | 0.02% | 220 |
|
|
2013
Q4 | $685K | Buy |
9,508
+2,412
| +34% | +$168K | 0.03% | 200 |
|
|
2013
Q3 | $488K | Buy |
+7,096
| New | +$469K | 0.02% | 211 |
|
Other funds holding NVS
Ferguson Wellman Capital Management's NVS Position: Q2 2026 in Review
Ferguson Wellman Capital Management reduced its Novartis (NVS) stake by 0.05% in Q2 2026, selling an estimated $14.4K and leaving 182,260 shares worth $28.6M. The position accounts for 0.35% of the portfolio, ranked #64.
Ferguson Wellman Capital Management first reported a position in NVS in Q3 2013 and has held it in 32 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Ferguson Wellman Capital Management held 182,260 shares of Novartis worth $28.6M as of Q2 2026.
- Ferguson Wellman Capital Management sold 96 Novartis shares in Q2 2026, an estimated $14.4K.
- Novartis made up 0.35% of Ferguson Wellman Capital Management's portfolio in Q2 2026, its #64 holding.
- Ferguson Wellman Capital Management first reported a position in Novartis in Q3 2013 and has held it in 32 quarters since.
- 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Ferguson Wellman Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.